91 Biggest Movers From Friday
Gainers
RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
83 Biggest Movers From Yesterday
Gainers
Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly traded company.
69 Biggest Movers From Friday
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Rubius Therapeutics To Present Trials In Progress Poster For The Phase 1/2 Clinical Trial Of Rtx-224 In Select Advanced Solid Tumors At The 2022 American Society Of Clinical Oncology Annual Meeting
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May
What 6 Analyst Ratings Have To Say About Rubius Therapeutics
Over the past 3 months, 6 analysts have published their opinion on Rubius Therapeutics (NASDAQ:RUBY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
SVB Leerink Maintains Market Perform on Rubius Therapeutics, Raises Price Target to $3
SVB Leerink maintains Rubius Therapeutics (NASDAQ:RUBY) with a Market Perform and raises the price target from $2 to $3.